openPR Logo
Press release

Almirall enters into Integrated Discovery Agreement with Proteros

09-23-2011 07:23 AM CET | Science & Education

Press release from: Proteros biostructures GmbH

Barcelona, September 22, 2011. Almirall, S.A. and Proteros biostructures GmbH today announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases.

Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to identify and optimize for selectivity and potency small molecule inhibitors of a specific enzyme.

Dr Jorge Beleta, Director Discovery Strategy and Alliances at Almirall remarked “we have worked with and been impressed by Proteros for many years on our structural biology and compound profiling projects and we see this broadening of our relationship to fully integrated projects as an exciting next step.”

Dr Torsten Neuefeind, Chief Executive Officer for Proteros commented ”we are delighted to be selected by Almirall as their partner for this programme. Proteros’s approach of knowledge driven fragment evolution has been validated within different protein classes and we look forward to demonstrating further success within this collaboration.”

About Proteros
Proteros is a privately held company, which provides services and proprietary technologies to support integrated drug discovery within life sciences. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.

About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.

Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.

Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.

Proteros biostructures GmbH
Thomas Waldmann, Ph.D.
Am Klopferspitz 19
82152 Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com

Almirall
Sonia Sansegundo/Vito Ballestero
Ketchum Pleon
Spain
Phone: +34 91 788 32 00
E-Mail: sonia.sansegundo@ketchumpleon.com
Internet: www.almirall.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Almirall enters into Integrated Discovery Agreement with Proteros here

News-ID: 192948 • Views: 1371

More Releases from Proteros biostructures GmbH

PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company. The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology. Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas. At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services. Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and

All 5 Releases


More Releases for Almirall

AI in Pharmaceutical Market - Current Impact to Make Big Changes | Bayer, Almira …
A new business intelligence report released by AMA with title "Global AI in Pharmaceutical Market Comprehensive Study" is designed covering micro level of analysis by manufacturers and key business segments. The Global AI in Pharmaceutical Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing.
Vaginal Rejuvenation Market 2018 to 2028 | Key Players - Almirall, Viveve Medica …
Vaginal Rejuvenation Market: Insights Vaginal rejuvenation is the procedure that comprises vaginal construction or reconstruction through invasive or non-invasive surgeries. According to the American Society for Aesthetic Plastic Surgery, vaginal rejuvenation is highly popular and is the latest cosmetic trend in the cosmetic and beauty market. The demand for vaginal rejuvenation is high. Nowadays, beauty is very important for women and the desire for beauty enhancement is not limited to the
Global Actinic Keratosis Therapeutics Market 2019 - Biofrontera, Almirall, Tolma …
Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck. In 2019, the market size of Actinic Keratosis Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR
Global Dermal Filler Market 2019 | medical equipment, Almirall Ltd, Aeon Astron …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as Dermal Filler - Medical Devices Pipeline Assessment, 2019 provides an in-depth analysis of the Dermal Filler with the forecast of market size and growth. The analysis includes addressable market, market by volume, market share by business type and by segment (external and in-house).The research study examines the Dermal Filler on the
Global Almagate Market 2018-2023 Almirall, Hanmi Pharm, Yuhan
Almagate Market Research 2018 A market study "Global Almagate Market" examines the performance of the Almagate market 2018. It encloses an in-depth Research of the Almagate market state and the competitive landscape globally. This report analyzes the potential of Almagate market in the present and the future prospects from various angles in detail. The Global Almagate Market 2018 report includes Almagate market Revenue, market Share, Almagate industry volume, market Trends, Almagate Growth
Global Actinic Keratosis Drugs Sales Market Report 2017- GALDERMA, Almirall, Val …
Apex Market Reports, recently published a detailed market research study focused on the "Actinic Keratosis Drugs Sales Market" across the global, regional and country level. The report provides 360° analysis of "Actinic Keratosis Drugs Sales Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Actinic Keratosis Drugs Sales industry, and estimates the